Life cycle analysis and sustainable packaging at AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical business with innovative medicines used by millions of patients worldwide. ERM is proud to be part of the team supporting two projects for the company. These projects were recently highlighted in AstraZeneca's 2015 environmental sustainability report.
In 2015, AstraZeneca selected five products that represent the breadth of the company's portfolio, and engaged ERM to conduct a full life cycle analysis for each product. The analysis focused on five key impact areas – climate change, water depletion, ecotoxicity, ozone depletion and resource depletion. The results of these assessments are now informing Astra Zeneca on where to focus efforts in reducing its environmental impact.
In 2010, AstraZeneca's Japan operation responded to patient feedback and competition with generics by launching an investigation into the optimum size, barrier material and packing line processes for tablet blister packaging produced for the Japanese market. ERM was hired to assist with this effort.
As a result, this year saw the launch of new packaging that delivers both significant cost savings and environmental benefits – including 50 percent reduced greenhouse gas emissions and 75 percent reduced resource use. In addition to delivering packing-line efficiencies, the new packaging also offers a 70 percent financial saving and is predicted to make significant financial savings in packaging material costs.